Cassava Sciences Inc

NASDAQ:SAVA  
25.12
+1.14 (+4.75%)
4:02:56 PM EDT: $25.30 +0.18 (+0.72%)
Products, Other Pre-Announcement

Cassava Sciences Announces Agreement With FDA On Special Protocol Assessments (SPA) For Its Phase 3 Studies Of Simufilam For The Treatment Of Alzheimer’s Disease

Published: 08/24/2021 14:54 GMT
Cassava Sciences Inc (SAVA) - Cassava Sciences Announces Agreement With FDA on Special Protocol Assessments (spa) for Its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease.
Cassava Sciences Announces Agreement With FDA on Special Protocol Assessments (spa) for Its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease.
Cassava Sciences Inc - Reaffirmed Prior Guidance to Advance Simufilam Into a Phase 3 Pivotal Program in Alzheimer's Disease in Fall 2021.